Fertin Pharma Issued U.S. Patent for Oral Delivery Tablet Formed by the Compression of Unique Sugar Alcohol Combinations

U.S. Patent No. 10,632,076 B2 further strengthens Fertin Pharma’s intellectual property (IP) portfolio

“We are very pleased to be able to develop this type of technology at Fertin,” said Jesper Neergaard, Senior Principal Scientist, Front End Innovation at Fertin. “Over the past few years, we have seen a clear shift in the consumer health market with an increased focus on convenience and pleasure, which often are not fulfilled by existing dosage formats like tablets or capsules. In the development process, we were able to overcome the technical challenges of combining active ingredients in oral and intra-oral delivery formats that are pleasurable for the consumer.”

The main objective of this technology is to provide oral delivery dosages with active ingredients that have a pleasurable taste and texture. The end product from the new patented technology is reflected in Fertin’s latest delivery technology, Zapliq®, a fast liquefiable chewable tablet. Zapliq® both in its chewable and gum version, has already shown to have a strong appeal for patients and consumers who require pharmaceuticals, vitamins, smoke inhibitors, dietary supplements, etc.

Fertin Pharma currently manages a portfolio of more than 100 patents within the fields of oral delivery formats, taste masking and release profiling. The company is continuously expanding its IP portfolio with the aim of providing its customers with a strong technology portfolio for the development of innovative dosage forms.

About Fertin Pharma

Fertin is a Danish contract development and manufacturing organization (CDMO) specializing in innovative oral dosage formats with nutraceutical and pharmaceutical ingredients. The company provides patients and consumers with convenient, pleasurable and efficient delivery formats, based on unique know-how, technological capabilities and consumer insight.

For further information, please visit www.fertin.com

Or contact:Jesper Neergaard, Senior Principal Scientist, Front End Innovation, Fertin Pharma, [email protected] Gosvig, Marketing Manager, Fertin Pharma, [email protected]